NCT04188249

Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis

A Prospective Multicenter Registry of Golimumab in Chinese Patients With Rheumatoid Arthritis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This will be a prospective, observational, single-arm, registry study based on data received from Chinese Registry of rheumatoid arthritis (CREDIT) database to register 200 Chinese RA patients treated with golimumab in one year. Patient characteristic, clinical effectiveness and drug adherence of golimumab will be evaluated.

Detailed description

This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Golimumab	This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.

Timeline

• Start date: 2019-07-01
• Primary completion: 2021-03-01
• Completion: 2021-03-01
• First posted: 2019-12-05
• Last updated: 2019-12-05

Locations

1 site across 1 country: China